Menu
Back to Journals » OncoTargets and Therapy » Volume 12
RETRACTED ARTICLE: Dihydrotanshinone I inhibits the growth of osteosarcoma through the Wnt/β-catenin signaling pathway
Authors Tan T, Chen J, Hu Y, Wang N, Chen Y, Yu T, Lin D, Yang S, Luo J, Luo X
Received 9 February 2019
Accepted for publication 28 May 2019
Published 2 July 2019 Volume 2019:12 Pages 5111—5122
DOI https://doi.org/10.2147/OTT.S204574
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Geoffrey Pietersz
This paper has been retracted.
Tan T, Chen J, Hu Y, et al. Onco Targets Ther. 2019;12:5111–5122.
The Editor and Publisher of OncoTargets and Therapy are retracting the published article. Concerns were raised regarding image duplication in Figure 2. Specifically,
- The image for Figure 2E, 143B, Control, has been duplicated with the same image for Figure 2E, 143B, 0µM.
- The image for Figure 2I, 143B, Control, has been duplicated with the same image for Figure 2I, 143B, 0µM.
The authors cooperated with the investigation and provided data associated with the reported study. However, despite the authors’ assistance, a satisfactory explanation for how the images came to be duplicated could not be provided, and the validity of the published work could not be verified. The decision was made to retract the article and the authors do not agree with this.
We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.
The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.
© 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.